Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID 19 Patients
COVID 19 has spurred much interest in the therapeutic potential of repurposed drugs. A family of acid reducing drugs, known as histamine H2 receptor antagonists (H2RA) competitively bind the H2R and block its stimulation by histamine; examples of such drugs are famotidine (e.g. Pepcid) and ranitidine (e.g. Zantac) A dense web of functionalities between histamine and H2RAs, on the one hand, and downstream cellular pathways, on the other hand, links disparate physiological pathways in gastrointestinal contexts (e.g. acid reduction) to the dysregulated inflammatory cascades (cytokine storm) underlying the pathophysiology of COVID 19. Is famotidine beneficial in treating COVID 19? This question remains unresolved, though not for lack of effort: over 10 studies have examined the potential therapeutic value of famotidine in COVID 19, but have found conflicting results (pro famotidine, anti famotidine, and neutral) Given the contradictory reports, we have undertaken the new analysis reported herein. Notably, studies published thus far rest upon substantially smaller datasets than drawn upon in the pre sent work. We analyzed a cohort of 22,560 COVID 19 patients taking H1/H2 receptor antagonists, focusing on 1,379 severe cases requiring respiratory support. We analyzed outcomes for treatment with the H1RAs loratadine (e.g. Claritin) and cetirizine (e.g. Zyrtec) the H2RA famotidine, aspirin, and a famotidine aspirin combination. For cases that reached the point of respiratory support, we found a significantly reduced fatality risk for famotidine treatment. We did not detect a benefit from dual histamine receptor blockade (concurrently targeting H1 and H2 receptors) Notably, famotidine combined with aspirin did exhibit a significant synergistic survival benefit (odds ratio of 0.55) The relative risk for death decreased by 32.5% an immense benefit, given the more than 2.6 million COVID 19 related deaths thus far. We found lower levels of serum markers for severe disease (e.g. C reactive protein) in famotidine users, consistent with prior findings by others and with a role for famotidine in attenuating cytokine release. The large, international, multi center retrospective study reported here, sampling over 250,000 COVID 19 cases, hopefully helps clarify the possible value of clinically approved histamine antagonists such as famotidine. Given these findings, alongside the cost effectiveness and mild side effects of popular drugs like famotidine and aspirin, we suggest that further prospective clinical trials, perhaps utilizing the aspirin combination reported here, are advisable.
medRxiv